NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Cytokinetics, Incorporated (CYTK) Stock Analysis

Cytokinetics, Incorporated (CYTK) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CYTK

$72.72

−$1.23 (−1.66%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CYTK with… →

CYTK Key Statistics

As of Sep 4, 2026
Trading
Open
$73.04
Previous Close
$73.95
Day's Range
72.26–74.01
52-Week Range
47.22–88.31
Volume
1.14M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.36
Valuation
Market Cap
$10.11B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
149.40
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.22
Financials (FY)
Revenue (FY)
$88.04M+376.56%
Net Income (FY)
−$784.96M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
139.02M
1-Year Return
+46.17%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
2.08M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CYTK Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+14.45%
2025+35.08%
2024−43.66%
2023+82.21%
2022+0.53%
2021+119.35%
2020+95.85%
2019+67.88%
2018−22.45%
2017−32.92%
2016 (partial year)+1.25%

As of September 4, 2026.

CYTK Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$88.04M−$784.96M−891.6%
2024$18.47M−$589.53M−3191.1%
2023$7.53M−$526.24M−6988.6%
2022$94.59M−$388.96M−411.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$88.04M−$327.99M−$612.26M−$784.96M−891.6%
2024$18.47M−$320.93M−$536.25M−$589.53M−3191.1%
2023$7.53M−$322.59M−$496.21M−$526.24M−6988.6%
2022$94.59M−$146.23M−$324.20M−$388.96M−411.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CYTK Valuation vs Biotechnology Median

Median of 656 stocks
MetricCYTKBiotechnology medianvs median
P/S ratio149.4015.269.8x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cytokinetics, Incorporated (CYTK) carries a market capitalisation of $10.11B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 673.

CYTK last closed at $72.72 on September 4, 2026. That is −$1.23 (−1.66%) against the previous close. Over the past 52 weeks the price has ranged from $47.22 to $88.31. The latest close sits 54% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $88.04M. Against the prior fiscal year total of $18.47M, that is a change of +376.56%. The same year closed with a net loss of $784.96M. The reported profit margin is 0%. Trailing earnings per share are −7.22.

Across the 4 fiscal years on file, revenue moves from $94.59M in 2022 to $88.04M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 149.4 times revenue. On price-to-sales that is 9.8 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned +46.17%. Across 10 years the annualized return works out at +21.51%. Beta against the wider market is reported at 0.36. Daily returns over the trailing 10 years annualize to a volatility of 67.86%.

Growth & Income

The record shows no dividend for CYTK.

The strongest complete calendar year on file is 2021 at +119.35%; the weakest is 2024 at −43.66%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the price is +14.45% year to date.

Peer Comparison

Cytokinetics, Incorporated (CYTK) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cytokinetics, Incorporated CYTK $10.11B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Cytokinetics, Incorporated has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Cytokinetics, Incorporated

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Visit website →